ULS_10.2-MED-Conferências
Permanent URI for this collection
Browse
Browsing ULS_10.2-MED-Conferências by Author "Amiot, A."
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational studyPublication . Dragoni, G.; Innocenti, T.; Amiot, A.; Castiglione, F.; Melotti, L.; Festa, S.; Savarino, E. V.; Truyens, M.; Argyriou, K.; Noviello, D.; Molnar, T.; Bouillon, V.; Bezzio, C.; Eder, P.; Fernandes, S.; Kagramanova, A.; Armuzzi, A.; Oliveira, R.; Viola, A.; Ribaldone, D. G.; Drygiannakis, I.; Viganò, C.; Calella, F.; Gravina, A. G.; Pugliese, D.; Chaparro, M.; Ellul, P.; Vieujean, S.; Milla, M.; Caprioli, F.Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.